Good Days Program Update
Due to funding changes, Good Days can no longer assist with Medicare coinsurance. Patients are now responsible for coinsurance at their visit, as required by law. Please call 757-481-4400 to discuss payment options.
Valeda Light Delivery Therapy at WKI: Advancing Care Pathways for Dry AMD
Dry age-related macular degeneration (AMD) continues to challenge both clinicians and patients, with limited tools available to meaningfully support retinal health in early and intermediate stages. At Wagner Kapoor Institute (WKI), we’ve introduced Valeda Light Delivery Therapy, the first FDA-cleared photobiomodulation (PBM) platform for dry AMD, to provide a proactive treatment option that aligns with our commitment to early intervention and functional preservation.
Mechanism of Action: Targeted Photobiomodulation
Valeda utilizes a proprietary blend of near-infrared, red, and yellow wavelengths to stimulate mitochondrial activity, enhance ATP production, and reduce oxidative stress—key drivers of dry AMD pathology. By improving retinal metabolism and reducing inflammation, PBM offers a cellular-level support strategy for patients who otherwise have few therapeutic options.
Clinical Evidence and Outcomes
Randomized controlled studies have demonstrated:
- Gains in best-corrected visual acuity for a subset of patients
- Improved contrast sensitivity
- Reduction in central drusen volume
- Enhanced structural and functional retinal parameters
Valeda is non-invasive, requires no dilation, and offers cumulative benefit through a series of short, staff-driven sessions.
Patient Selection at WKI
At WKI, we recommend Valeda for:
- Patients with intermediate dry AMD
- Those experiencing functional decline not fully explained by OCT anatomy
- Patients seeking an evidence-based adjunct to AREDS2 supplementation
- Individuals interested in proactive intervention to support long-term retinal function
Valeda is not indicated for neovascular AMD or advanced geographic atrophy, though research is ongoing.
Seamless Clinical Integration
WKI has incorporated Valeda into our dry AMD care model with strong patient satisfaction. Each treatment lasts approximately 4–5 minutes per eye.
WKI is proud to offer this technology as part of our continued mission to deliver forward-thinking retinal care.
You Might Also Enjoy...
Diet Soda Linked to Increased Risk for Diabetic Retinopathy
Drinking diet soda may increase the risk for proliferative diabetic retinopathy — a severe type of diabetic eye disease that can lead to blindness.
Vision Health is Detrimental to the Aging Population's Wellbeing
The aging population's eye health can be a determinant in their overall wellbeing. A healthy eye is a happy eye!
Ocular Melanoma
When we think of melanoma, we think primarily of melanoma affecting the skin.
If It’s good enough for astronauts, it must be good enough for all of us!
Being able to determine how someone’s health is when that someone is far away requires knowing what to measure, how to measure it, and how to get that information where it needs to go.
How Colon Cancer Treatment Redefined Preventable Blindness Worldwide
In 2013, a group of prominent historians were surveyed and asked to compile a list of the greatest breakthroughs of all time....